Duration of anticoagulant treatment and recurrence of venous thromboembolism in patients with and without thrombophilic abnormalities

Duration of anticoagulant treatment and recurrence of venous thromboembolism in patients with and without thrombophilic abnormalities -

[1]  Paolo Prandoni,et al.  The risk of recurrent venous thromboembolism among heterozygous carriers of factor V Leiden or prothrombin G20210A mutation. A systematic review of prospective studies. , 2007, Haematologica.

[2]  G. Hankey,et al.  Risk of recurrent venous thromboembolism in patients with common thrombophilia: a systematic review. , 2006, Archives of internal medicine.

[3]  Frits R Rosendaal,et al.  Thrombophilia, clinical factors, and recurrent venous thrombotic events. , 2005, JAMA.

[4]  W. Ageno,et al.  Thrombophilic abnormalities and recurrence of venous thromboembolism in patients treated with standardized anticoagulant treatment. , 2005, Thrombosis research.

[5]  C. Kearon.  Long-term management of patients after venous thromboembolism. , 2004, Circulation.

[6]  J. Heit,et al.  Thrombophilia and new anticoagulant drugs. , 2004, Hematology. American Society of Hematology. Education Program.

[7]  T. Baglin,et al.  Incidence of recurrent venous thromboembolism in relation to clinical and thrombophilic risk factors: prospective cohort study , 2003, The Lancet.

[8]  W. Ageno,et al.  Extended Oral Anticoagulant Therapy after a First Episode of Pulmonary Embolism , 2003, Annals of Internal Medicine.

[9]  F. Spencer,et al.  Risk Factors for Venous Thromboembolism , 2003, Circulation.

[10]  M. Prins,et al.  The incidence of recurrent venous thromboembolism in carriers of factor V Leiden is related to concomitant thrombophilic disorders , 2002, British journal of haematology.

[11]  P. Prandoni,et al.  Three months vs. one year of oral anticoagulant therapy for idiopathic deep venous thrombosis , 2002 .

[12]  W. Ageno,et al.  Three months versus one year of oral anticoagulant therapy for idiopathic deep venous thrombosis. Warfarin Optimal Duration Italian Trial Investigators. , 2001, The New England journal of medicine.

[13]  G Leone,et al.  The risk of recurrent deep venous thrombosis among heterozygous carriers of both factor V Leiden and the G20210A prothrombin mutation. , 1999, The New England journal of medicine.

[14]  B. Wiman,et al.  The Risk of Recurrent Venous Thromboembolism in Carriers and Non-carriers of the G1691A Allele in the Coagulation Factor V Gene and the G20210A Allele in the Prothrombin Gene , 1999, Thrombosis and Haemostasis.

[15]  M Gent,et al.  A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. , 1999, The New England journal of medicine.

[16]  S. Eichinger,et al.  Hyperhomocysteinemia Is a Risk Factor of Recurrent Venous Thromboembolism , 1998, Thrombosis and Haemostasis.

[17]  T. Baglin,et al.  Risk of recurrent venous thromboembolism in patients with the factor V Leiden (FVR506Q) mutation: effect of warfarin and prediction by precipitating factors , 1998, British journal of haematology.

[18]  M. Prins,et al.  Recurrence of venous thromboembolism in patients with familial thrombophilia. , 1997, Archives of internal medicine.

[19]  E. Minar,et al.  The Risk of Recurrent Venous Thromboembolism in Patients with and without Factor V Leiden , 1997, Thrombosis and Haemostasis.

[20]  M. Prins,et al.  The risk of recurrent venous thromboembolism in patients with an Arg506-->Gln mutation in the gene for factor V (factor V Leiden). , 1997, The New England journal of medicine.

[21]  C. Mannhalter,et al.  Probability of Recurrence of Thrombosis in Patients with and without Factor V Leiden , 1996, Thrombosis and Haemostasis.

[22]  P. Ridker,et al.  Factor V Leiden and risks of recurrent idiopathic venous thromboembolism. , 1995, Circulation.

[23]  T. Barbui,et al.  Clinical Manifestations and Management of Inherited Thrombophilia: Retrospective Analysis and Follow-up after Diagnosis of 238 Patients with Congenital Deficiency of Antithrombin III, Protein C, Protein S , 1994, Thrombosis and Haemostasis.